American Heart Journal
Volume 156, Issue 2 , Pages 241-247 , August 2008

Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy

  • Sripal Bangalore, MD, MHA

      Affiliations

    • Division of Cardiovascular Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY
    • ,
  • Franz H. Messerli, MD

      Affiliations

    • Division of Cardiovascular Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY
    • Corresponding Author InformationReprint requests: Franz H. Messerli, MD, Hypertension Program, Division of Cardiology, Columbia University College of Physicians and Surgeons, St. Luke's-Roosevelt Hospital Center, 1000 Tenth Avenue, Suite 3B-30, New York, NY 10025.
    • ,
  • Jerome D. Cohen, MD

      Affiliations

    • Department of Medicine, Saint Louis University, St Louis, MO
    • ,
  • Peter H. Bacher, MD, PhD

      Affiliations

    • Abbott Laboratories, Abbott Park, Chicago, IL
    • ,
  • Peter Sleight, MD

      Affiliations

    • Department of Medicine, Lankenau Hospital, Wynnewood, PA
    • ,
  • Giuseppe Mancia, MD, PhD

      Affiliations

    • Department of Medicine, Universita Degli Studi, Monza, Italy
    • ,
  • Peter Kowey, MD

      Affiliations

    • Main Line Health Heart Center, Wynnewood, Philadelphia, PA
    • ,
  • Qian Zhou, PhD

      Affiliations

    • Abbott Laboratories, Abbott Park, Chicago, IL
    • ,
  • Annette Champion, MBA

      Affiliations

    • Abbott Laboratories, Abbott Park, Chicago, IL
    • ,
  • Carl J. Pepine, MD

      Affiliations

    • Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL
    • ,
  • for the INVEST Investigators

Received 16 November 2007 ,Accepted 25 February 2008.

References 

  1. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  2. Chen J, Radford MJ, Wang Y, et al. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction?. Arch Intern Med. 2000;160:947–952
  3. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  4. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903–1907
  5. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454e1–454e8
  6. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153–1158
  7. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304:405–412
  8. Messerli FH, Grossman E. Beta-blocker therapy and depression. JAMA. 2002;288:1845–1846author reply 1846
  9. Hurst W. The heart, arteries and veins. 10 ed. New York: McGraw-Hill; 2002;
  10. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–1331
  11. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 1995;43:1191–1197
  12. Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:1061–1065
  13. Pepine CJ, Abrams J, Marks RG, et al. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol. 1994;74:226–231
  14. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620–625
  15. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–2816
  16. Pepine CJ, Handberg-Thurmond E, Marks RG, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32:1228–1237
  17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446
  18. Ried LD, Tueth MJ, Handberg E, et al. Validating a self-report measure of global subjective well-being to predict adverse clinical outcomes. Qual Life Res. 2006;15:675–686
  19. Elliott WJ, Hewkin AC, Kupfer S, et al. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. J Clin Hypertens (Greenwich). 2005;7:654–663
  20. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053
  21. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–1553
  22. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  23. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225
  24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  25. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104:522–526
  26. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592

 This work was presented in part at the 2007 Annual Scientific Session of the American College of Cardiology in New Orleans, LA, on March 26, 2007.

 This study was supported by grants from the University of Florida (Gainesville, FL) and Abbott Laboratories (Abbott Park, IL).

PII: S0002-8703(08)00225-1

doi: 10.1016/j.ahj.2008.02.023

American Heart Journal
Volume 156, Issue 2 , Pages 241-247 , August 2008

Article Tools

* Image Usage & Resolution